At what enterprise value was NUTRISENS acquired in 2021?

During the acquisition of NUTRISENS by SAGARD in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NUTRISENS when it was acquired by SAGARD?

The estimated EV/EBITDA multiple for NUTRISENS is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was NUTRISENS acquired by SAGARD?

NUTRISENS was acquired by SAGARD in 2021.

What was the revenue of NUTRISENS at the time of the deal?

The revenue of NUTRISENS at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of NUTRISENS during the acquisition?

NUTRISENS's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NUTRISENS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NUTRISENS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/sagard-preempte-nutrisens-et-le-valorise-140-150-m-1284516

← DATABASE

Home Database Healthcare & PharmaNUTRISENS

01/2021

NUTRISENS acquired by SAGARD

FRANCE Life Sciences / Nutrition & Dietary Supplements EV 100M - 350M EUR

Context

Sagard entered into exclusive negotiations to acquire a majority stake in Nutrisens, effectively preempting an auction process that had attracted ten funds and three industrial players. The transaction marks the exit of historical shareholder Evolem (family office of Bruno Rousset), which had built the group since 2007, and minority investor Unigrains (who held 30%). The management team is reinvesting alongside Sagard. To secure the deal quickly, Sagard arranged a unitranche financing facility with Idinvest Partners. The strategic plan aims to exceed EUR100 million in revenue in 2021 through new acquisitions and by expanding distribution into pharmacies.

NUTRISENS, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European specialist in clinical nutrition and "medical food". Founded in 2011, the group develops specific nutritional products for patients suffering from pathologies such as dysphagia (swallowing difficulties), malnutrition, or renal failure. It serves hospitals, nursing homes (EHPAD), and pharmacies. The group has a strong Corporate footprint in France and Spain.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with NUTRISENS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2025	CINVEN	NUTRISENS	FRANCE	Life Sciences	Cinven acquires a majority stake in the French clinical nutrition group Nutrisens from Sagard. The transaction values the company at over EUR700 million. Under Sagard's tenure, Nutrisens tripled its size through organic growth and acquisitions. With Cinven's backing, the group aims to become a global platform in the fragmented medical nutrition market, targeting further acquisitions in Europe and expanding into new therapeutic areas.
03/2025	NUTRISENS	PRODIET	BRAZIL	Life Sciences	Nutrisens Group has acquired a majority stake in Prodiet Medical Nutrition, a Brazilian leader in clinical nutrition. The founders of Prodiet, Armando Tortelli and Ana Paula Celes, retain a minority stake and will continue to support the company's growth, while Gabriel Tortelli remains as CEO. This acquisition marks a major step in Nutrisens' international expansion strategy, providing a strong platform to address the Latin American market. The deal is expected to generate significant commercial synergies through cross-selling portfolios and optimizing innovation and sourcing capabilities.

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NUTRISENS by SAGARD are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: sagard